Undervalued Biotechnology Stocks on TSE September 2023

September 09, 2023

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

Toronto Stock Exchange

The Toronto Stock Exchange (TSE) is a stock exchange located in Toronto, Ontario, Canada. It is the 10th largest exchange in the world and the third largest in North America based on market capitalization.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
AEZS AEterna Zentaris 3.39 6.54 92.94 543 16 0.00 0.0
RVX Resverlogix 0.07 0.14 83.00 124211 20 0.00 0.0
ATE Antibe Therapeutics 0.56 1.00 78.89 20794 29 0.00 0.0
MDNA Medicenna Therapeutics 0.41 0.67 61.03 47254 29 0.00 0.0
APS Aptose Biosciences 4.80 7.12 48.29 1986 30 0.00 0.0
APLI Appili Therapeutics 0.06 0.07 26.70 122845 7 0.00 0.0
SVA Sernova 0.86 1.01 16.94 69506 261 0.00 0.0
MBX Microbix Biosystems 0.31 0.35 12.80 32296 43 0.00 0.0
PMN ProMIS Neurosciences 6.24 6.47 3.73 10525 54 0.00 0.0
IPCI IntelliPharmaCeutics Intl 0.11 0.11 1.14 4605 4 0.00 0.0
All data provided as at market close September 07, 2023.

Company Details

AEterna Zentaris

AEZS:TSX

Close Price

3.39

Our Valuation

6.54

% Difference

92.94

Market Cap ($M)

16

P/E Ratio

0.0

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada.

Access the stockcalc valuation


Resverlogix

RVX:TSX

Close Price

0.07

Our Valuation

0.14

% Difference

83.00

Market Cap ($M)

20

P/E Ratio

0.0

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.

Access the stockcalc valuation


Antibe Therapeutics

ATE:TSX

Close Price

0.56

Our Valuation

1.00

% Difference

78.89

Market Cap ($M)

29

P/E Ratio

0.0

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain.

Access the stockcalc valuation


Medicenna Therapeutics

MDNA:TSX

Close Price

0.41

Our Valuation

0.67

% Difference

61.03

Market Cap ($M)

29

P/E Ratio

0.0

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Aptose Biosciences

APS:TSX

Close Price

4.80

Our Valuation

7.12

% Difference

48.29

Market Cap ($M)

30

P/E Ratio

0.0

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Access the stockcalc valuation


Appili Therapeutics

APLI:TSX

Close Price

0.06

Our Valuation

0.07

% Difference

26.70

Market Cap ($M)

7

P/E Ratio

0.0

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.

Access the stockcalc valuation


Sernova

SVA:TSX

Close Price

0.86

Our Valuation

1.01

% Difference

16.94

Market Cap ($M)

261

P/E Ratio

0.0

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells.

Access the stockcalc valuation


Microbix Biosystems

MBX:TSX

Close Price

0.31

Our Valuation

0.35

% Difference

12.80

Market Cap ($M)

43

P/E Ratio

0.0

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen and QAPs and Other. It generates maximum revenue from the Antigen and QAPs segment. Geographically, it derives a majority of revenue from North America.

Access the stockcalc valuation


ProMIS Neurosciences

PMN:TSX

Close Price

6.24

Our Valuation

6.47

% Difference

3.73

Market Cap ($M)

54

P/E Ratio

0.0

ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It operates in Canada.

Access the stockcalc valuation


IntelliPharmaCeutics Intl

IPCI:TSX

Close Price

0.11

Our Valuation

0.11

% Difference

1.14

Market Cap ($M)

4

P/E Ratio

0.0

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
AEterna Zentaris and Resverlogix are the most undervalued Biotechnology stocks on the TSE. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tse-september-2023
AEterna Zentaris $AEZS and Resverlogix $RVX are the most undervalued Biotechnology stocks on the #TSE. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tse-september-2023
AEterna Zentaris and Resverlogix are the most undervalued Biotechnology stocks on the TSE. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tse-september-2023

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.